Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 200,000 shares at $69.59 ($13.2M) on 2021-03-01, disclosed to the SEC on 2021-03-03.
Open-market sale of $13.2M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.36 | 18,770 | $1.2M | 9.1% |
| 2 | $64.36 | 18,770 | $1.2M | 9.1% |
| 3 | $65.63 | 37,445 | $2.5M | 18.6% |
| 4 | $65.63 | 37,445 | $2.5M | 18.6% |
| 5 | $66.55 | 18,316 | $1.2M | 9.2% |
| 6 | $66.55 | 18,316 |
| $1.2M |
| 9.2% |
| 7 | $67.57 | 14,945 | $1.0M | 7.6% |
| 8 | $67.57 | 14,945 | $1.0M | 7.6% |
| 9 | $68.50 | 6,011 | $412K | 3.1% |
| 10 | $68.50 | 6,011 | $412K | 3.1% |
| 11 | $69.59 | 3,482 | $242K | 1.8% |
| 12 | $69.59 | 3,482 | $242K | 1.8% |
| 13 | $71.35 | 1,031 | $74K | 0.6% |
| 14 | $71.35 | 1,031 | $74K | 0.6% |
| Total | $66.22 avg | 200,000 | $13.2M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |